Holen Sie sich die Stockscreener-App
3.915
3.59%
-0.155
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.07
Offen:
$4.2
24-Stunden-Volumen:
6.68M
Relative Volume:
0.46
Marktkapitalisierung:
$1.61B
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-3.1829
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
-23.51%
1M Leistung:
+52.67%
6M Leistung:
+72.85%
1J Leistung:
+11.47%
1-Tages-Spanne:
$3.91
$4.21
1-Wochen-Bereich:
$3.925
$5.63
52-Wochen-Spanne:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.915 | 1.68B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.99 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.04 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.13 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.61 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5%What's Next? - MarketBeat
Iovance Biotherapeutics at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - Sahm
Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan - Sahm
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com Nigeria
Iovance Biotherapeutics Shines with TIL Therapy Success and Financial Gain - timothysykes.com
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - Yahoo Finance
Is It Too Late To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Sahm
Iovance (IOVA) Soars 33%, Hits All-Time High - Insider Monkey
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Finviz
Iovance (IOVA) hits 52-week high as analyst doubles price target - MSN
Momentum Shift: Is Iovance Biotherapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Naître et grandir
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum - International Business Times Australia
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative
Iovance Biotherapeutics Expands Clinical Trials Amid Strategic Upgrades - timothysykes.com
What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
Iovance Biotherapeutics Shines with Positive Trial Outcomes and Upgraded Ratings - StocksToTrade
UBS Raises PT on Iovance Biotherapeutics (IOVA) - Insider Monkey
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD By Investing.com - Investing.com Canada
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - Yahoo Finance
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - The Motley Fool
Key facts: Iovance Biotherapeutics expands TIL therapy; UBS raises price target - TradingView
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $4.00 at UBS Group - MarketBeat
UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating - marketscreener.com
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat
A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - simplywall.st
Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance
IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):